Can long-term COVID-19 vaccination be improved by serological surveillance?: a modeling study for Mozambique
暂无分享,去创建一个
S. Jenness | K. Shioda | S. Flasche | I. Mandomando | B. Lopman | K. Nelson | Sérgio Massora | A. Kraay | Arsénia J Massinga | Carol Y. Liu | S. Omer | C. Monjane | Áuria de Jesus
[1] Andrea A. Berry,et al. Persistence of antibody responses to COVID-19 vaccines among participants in the COVID-19 Community Research Partnership. , 2023, Vaccine: X.
[2] B. Lopman,et al. Serological Studies and the Value of Information. , 2023, American journal of public health.
[3] Andrea A. Berry,et al. Estimated COVID-19 vaccine effectiveness against seroconversion from SARS-CoV-2 Infection, March–October, 2021 , 2023, Vaccine.
[4] A. Ghani. Long term vaccination strategies to mitigate the impact of SARS-CoV-2 transmission: a modelling study , 2023, medRxiv.
[5] G. Hather,et al. The impact of vaccination frequency on COVID-19 public health outcomes: A model-based analysis , 2023, medRxiv.
[6] Zahra A. Premji,et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression , 2023, The Lancet Infectious Diseases.
[7] M. Exline,et al. Effectiveness of Monovalent mRNA Vaccines Against COVID-19-Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States - IVY Network, 18 States, December 26, 2021-August 31, 2022. , 2022, MMWR. Morbidity and mortality weekly report.
[8] A. Azman,et al. Building an integrated serosurveillance platform to inform public health interventions: Insights from an experts’ meeting on serum biomarkers , 2022, PLoS neglected tropical diseases.
[9] H. Zar,et al. Natural and hybrid immunity following four COVID-19 waves: A prospective cohort study of mothers in South Africa , 2022, eClinicalMedicine.
[10] D. Skowronski,et al. Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study , 2022, The Lancet Infectious Diseases.
[11] Quentin J. Leclerc,et al. Modelling the medium-term dynamics of SARS-CoV-2 transmission in England in the Omicron era , 2022, Nature Communications.
[12] E. Karlson,et al. Longitudinal SARS-CoV-2 Nucleocapsid Antibody Kinetics, Seroreversion, and Implications for Seroepidemiologic Studies , 2022, Emerging infectious diseases.
[13] K. Lythgoe,et al. SARS-CoV-2 antibody trajectories after a single COVID-19 vaccination with and without prior infection , 2022, Nature Communications.
[14] I. Jani,et al. Prevalence of SARS-CoV-2 antibodies in the Mozambican population: a cross-sectional Serologic study in three cities, July-August 2020 , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] Gheyath K Nasrallah,et al. Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections , 2022, The New England journal of medicine.
[16] C. Viboud,et al. Projecting the SARS-CoV-2 transition from pandemicity to endemicity: Epidemiological and immunological considerations , 2022, PLoS pathogens.
[17] O. Watson,et al. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study , 2022, The Lancet Infectious Diseases.
[18] E. Boerwinkle,et al. Antibody Duration After Infection From SARS-CoV-2 in the Texas Coronavirus Antibody Response Survey , 2022, The Journal of infectious diseases.
[19] K. Bibbins-Domingo,et al. COVID-19 Vaccination and Estimated Public Health Impact in California , 2022, JAMA network open.
[20] N. Dean,et al. The changing epidemiology of SARS-CoV-2 , 2022, Science.
[21] P. Diggle,et al. Population antibody responses following COVID-19 vaccination in 212,102 individuals , 2022, Nature communications.
[22] A. Charlett,et al. Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection , 2022, The New England journal of medicine.
[23] C. M. Saad-Roy,et al. Modelling vaccination strategies for COVID-19 , 2022, Nature Reviews Immunology.
[24] K. Brown,et al. Protective effect of a first SARS-CoV-2 infection from reinfection: a matched retrospective cohort study using PCR testing data in England , 2022, Epidemiology and Infection.
[25] H. Gómez-Dantés,et al. The Role of Serology Testing in the Context of Immunization Policies for COVID-19 in Latin American Countries , 2021, Viruses.
[26] Han Liu,et al. Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States , 2021, International Journal of Infectious Diseases.
[27] Jue Liu,et al. Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis , 2021, Infectious Diseases of Poverty.
[28] K. Lythgoe,et al. Anti-spike antibody response to natural SARS-CoV-2 infection in the general population , 2021, Nature Communications.
[29] S. Truelove,et al. A systematic review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and disease , 2021, medRxiv.
[30] M. Halloran,et al. Transition to endemicity: Understanding COVID-19 , 2021, Immunity.
[31] William F. Fadel,et al. Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings , 2021, The New England journal of medicine.
[32] M. Abu-Farha,et al. Previous COVID-19 Infection and Antibody Levels After Vaccination , 2021, Frontiers in Public Health.
[33] G. Ayenigbara,et al. The challenges to a successful COVID-19 vaccination programme in Africa. , 2021, Germs.
[34] D. Stuart,et al. Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom , 2021, Nature Microbiology.
[35] E. Holmes,et al. After the pandemic: perspectives on the future trajectory of COVID-19 , 2021, Nature.
[36] Paul J. Birrell,et al. Anti-spike antibody response to natural SARS-CoV-2 infection in the general population , 2021, medRxiv.
[37] J. Nkengasong,et al. COVID-19 vaccine access in Africa: Global distribution, vaccine platforms, and challenges ahead , 2021, Immunity.
[38] A. Hayward,et al. Spike-antibody waning after second dose of BNT162b2 or ChAdOx1 , 2021, The Lancet.
[39] S. Pei,et al. Role of meteorological factors in the transmission of SARS-CoV-2 in the United States , 2021, Nature Communications.
[40] Tangchun Wu,et al. Dynamics of the SARS-CoV-2 antibody response up to 10 months after infection , 2021, Cellular & Molecular Immunology.
[41] M. V. Van Kerkhove,et al. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021 , 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[42] M. Davenport,et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection , 2021, Nature Medicine.
[43] A. Fiore-Gartland,et al. Evidence for antibody as a protective correlate for COVID-19 vaccines , 2021, Vaccine.
[44] Weizhong Yang,et al. Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study , 2021, The Lancet.
[45] Y. Ge,et al. Modeling the use of SARS-CoV-2 vaccination to safely relax non-pharmaceutical interventions , 2021, medRxiv.
[46] 12,et al. SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay , 2021, medRxiv.
[47] M. Van Ranst,et al. Longitudinal follow-up of IgG anti-nucleocapsid antibodies in SARS-CoV-2 infected patients up to eight months after infection , 2021, Journal of Clinical Virology.
[48] C. M. Saad-Roy,et al. Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes , 2021, medRxiv.
[49] O. Bjørnstad,et al. Immunological characteristics govern the transition of COVID-19 to endemicity , 2021, Science.
[50] M. Veldhoen,et al. Endemic SARS-CoV-2 will maintain post-pandemic immunity , 2021, Nature Reviews Immunology.
[51] Yi Bai,et al. SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans , 2020, Research square.
[52] D. Stuart,et al. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers , 2020, The New England journal of medicine.
[53] K. Koelle,et al. Indirect benefits are a crucial consideration when evaluating SARS-CoV-2 vaccine candidates , 2020, Nature Medicine.
[54] Z. Livneh,et al. Multi-center nationwide comparison of seven serology assays reveals a SARS-CoV-2 non-responding seronegative subpopulation , 2020, EClinicalMedicine.
[55] P. Kellam,et al. Antibody response to SARS-CoV-2 infection in humans: A systematic review , 2020, medRxiv.
[56] F. Miralles-Wilhelm,et al. Temperature, Humidity, and Latitude Analysis to Estimate Potential Spread and Seasonality of Coronavirus Disease 2019 (COVID-19) , 2020, JAMA network open.
[57] M. Roser,et al. Coronavirus Pandemic (COVID-19) , 2020 .
[58] A. Azman,et al. Serology for SARS-CoV-2: Apprehensions, opportunities, and the path forward , 2020, Science Immunology.
[59] F. Yu,et al. Serology characteristics of SARS-CoV-2 infection since exposure and post symptom onset , 2020, European Respiratory Journal.
[60] Rachel E. Baker,et al. Susceptible supply limits the role of climate in the early SARS-CoV-2 pandemic , 2020, Science.
[61] Yonatan H. Grad,et al. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period , 2020, Science.
[62] J. Rocklöv,et al. The reproductive number of COVID-19 is higher compared to SARS coronavirus , 2020, Journal of travel medicine.
[63] J. Lessler,et al. Impact on Epidemic Measles of Vaccination Campaigns Triggered by Disease Outbreaks or Serosurveys: A Modeling Study , 2016, PLoS medicine.
[64] O Diekmann,et al. The construction of next-generation matrices for compartmental epidemic models , 2010, Journal of The Royal Society Interface.
[65] Pejman Rohani,et al. Appropriate Models for the Management of Infectious Diseases , 2005, PLoS medicine.
[66] M. Stein. Large sample properties of simulations using latin hypercube sampling , 1987 .